Join Growin Stock Community!

Vera therapeutics, inc.VERA.US Overview

US StockHealthcare
(No presentation for VERA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VERA AI Insights

VERA Overall Performance

VERA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VERA Recent Performance

-1.25%

Vera therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

VERA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VERA Key Information

VERA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VERA Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Price of VERA

VERA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VERA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.53
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.28
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.53
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is VERA's latest earnings report released?

    The most recent financial report for Vera therapeutics, inc. (VERA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VERA's short-term business performance and financial health. For the latest updates on VERA's earnings releases, visit this page regularly.

  • How much debt does VERA have?

    As of the end of the reporting period, Vera therapeutics, inc. (VERA) had total debt of 77.31M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VERA have?

    At the end of the period, Vera therapeutics, inc. (VERA) held Total Cash and Cash Equivalents of 354.73M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is VERA's EPS continuing to grow?

    According to the past four quarterly reports, Vera therapeutics, inc. (VERA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VERA?

    Vera therapeutics, inc. (VERA)'s Free Cash Flow (FCF) for the period is -70.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 76% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VERA?

    The latest valuation data shows Vera therapeutics, inc. (VERA) has a Price-To-Earnings (PE) ratio of -10.09 and a Price/Earnings-To-Growth (PEG) ratio of -0.87. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.